



GLOBAL VACCINE SAFETY INITIATIVE

2017
MEETING REPORT



World Health
Organization

WHO/EMP/SAV/2018.2

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Global Vaccine Safety Initiative. Report of a meeting, Kuala Lumpur, Malaysia, 11-12 October 2017. Geneva: World Health Organization; 2018 (WHO/EMP/SAV/2018.2). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Layout by [Paprika, Annecy](#), France

Photos credits: Cover photo: Adobe Stock / p.5-14-67-68-69: Mr Kuilan Yogeswaran / p.17-p.33: Shutterstock / p.18: Mr Noam Le Pottier / p.25, 37: Dr Madhava Balakrishnan / p.21-27-39-41-43-65-71-74-77-81: Adobe Stock / p.51: Dr Christine Guillard-Maure/WHO / p.55: Bill & Melinda Gates Foundation

Printed in Switzerland

GLOBAL VACCINE SAFETY INITIATIVE

2017
MEETING REPORT



World Health
Organization

Meeting objectives:

1. Review progress in GVSI implementation.
2. Address new challenges and opportunities in vaccine safety.
3. Facilitate further partnerships and inter-sectoral collaboration.
4. Identify means to promote regulatory harmonization initiatives for strengthening vaccine pharmacovigilance.

Introduction

The sixth meeting of the Global Vaccine Safety Initiative (GVSI) was held in Kuala Lumpur from 11 to 12 October 2017. It was hosted by the Ministry of Health of Malaysia in cooperation with the Association of Southeast Asian Nations (ASEAN) Pharmaceutical Product Working Group.

It provided an important platform for exchange, interaction and information between Member States and partners, as well as opportunities for partnership-building and planning.

Guided by four specific objectives, participants reported on initiatives relevant to the Global Vaccine Safety Blueprint objectives, shared experiences to strengthen vaccine pharmacovigilance, and identified needs and opportunities for further development.

Attendees included: immunization program managers, national regulatory authorities' pharmacovigilance staff from 24 countries, representatives of UN agencies, academic institutions, umbrella organizations of pharmaceutical companies, technical partners, industry representatives and funding agencies.

This report provides an overview of the key points discussed during the event and summarizes its conclusions.



OPENING

SESSION 1
LESSONS LEARNT

SESSION 2
GACVS

SESSION 3
SAFETY COMMUNICATION

SESSION 4
BREAKOUT

SESSION 5
ENHANCED SURVEILLANCE

SESSION 6
PROJECT GALLERY

SESSION 7
GLOBAL OBSERVATORY

CONCLUSION & APPENDICES



Contents

Opening

8

The Global Vaccine Safety Initiative: review of achievements in 201712

Promoting regulatory collaboration and harmonization in ASEAN countries:
the ASEAN pharmaceutical product working group 18

DAY 1 / SESSION 1 – Lessons learned from country experiences 22

Vaccine confidence building and crisis response
during immunization campaign in Malawi.....24

Improving communication capacities during AEFI investigation in Ghana26

Facing the anti-vaccine lobby in Bosnia and Herzegovina.....28

Developing pharmacovigilance inspection capacities in Malaysia.....30

Avoiding vaccine safety crisis through timely investigation,
communication and post-mortem in Fiji 32

DAY 1 / SESSION 2 – Safety issues of current interest 34

The Global Advisory Committee of Vaccine Safety: mandate, composition,
operations, topics reviewed and topics of current interest.....36

DAY 1 / SESSION 3 – Vaccine safety communication 40

Developing coordinated strategies to overcome vaccine safety confidence barriers.....42

DAY 1 / SESSION 4 – Breakout sessions 46

Vaccine safety system strengthening: progress and plans in countries of the western
pacific region.....48

Improving vaccine safety in countries of the african region..... 50

New landscape for immunization during pregnancy: discussing needs and
opportunities for appropriate safety monitoring54

DAY 2 / SESSION 5 – Enhancing safety surveillance capacities 58

The Bill and Melinda Gates Foundation initiative to enhance pharmacovigilance in low- and middle-income country settings.....	60
The CIOMS guide to active vaccine safety surveillance	62
Generating information for action: WHO AEFI data management training	66

DAY 2 / SESSION 6 – Project Gallery 70

DAY 2 / SESSION 7 – Global vaccine safety monitoring 74

The Global Vaccine Safety Observatory	76
---	----

CONCLUSIONS 80

APPENDICES 84

Appendix 1: List of participants.....	86
Appendix 2: Acronyms.....	108

OPENING

SESSION 1
LESSONS LEARNT

SESSION 2
GACVS

SESSION 3
SAFETY COMMUNICATION

SESSION 4
BREAKOUT

SESSION 5
ENHANCED SURVEILLANCE

SESSION 6
PROJECT GALLERY

SESSION 7
GLOBAL OBSERVATORY

CONCLUSION & APPENDICES

OPENING

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26038

